about
Next-generation sequencing: advances and applications in cancer diagnosisThe next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy responseGenetic profiling of a rare condition: co-occurrence of albinism and multiple primary melanoma in a Caucasian family.Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients.Proteomic profile and in silico analysis in metastatic melanoma with and without BRAF mutationMicroRNA expression profiling in male and female familial breast cancer.MiR-578 and miR-573 as potential players in BRCA-related breast cancer angiogenesisBRCA1-2 diagnostic workflow from next-generation sequencing technologies to variant identification and final report.u-PAR expression in cancer associated fibroblast: new acquisitions in multiple myeloma progressionGATK hard filtering: tunable parameters to improve variant calling for next generation sequencing targeted gene panel data.Immunoprofile from tissue microarrays to stratify familial breast cancer patientsRole of miR-27a, miR-181a and miR-20b in gastric cancer hypoxia-induced chemoresistance.Expression of base excision repair key factors and miR17 in familial and sporadic breast cancermiR-151-5p, targeting chromatin remodeler SMARCA5, as a marker for the BRCAness phenotype.BRCAness: a deeper insight into basal-like breast tumors.DNA methylation and miRNAs regulation in hereditary breast cancer: epigenetic changes, players in transcriptional and post- transcriptional regulation in hereditary breast cancer.The value of new high-throughput technologies for diagnosis and prognosis in solid tumors.miRNA profiling in serum and tissue samples to assess noninvasive biomarkers for NSCLC clinical outcome.Nuclear PARP1 expression and its prognostic significance in breast cancer patients.Six low-penetrance SNPs for the estimation of breast cancer heritability: A family-based study in Caucasian Italian patients.Genetic risk transmission in a family affected by familial breast cancer.DHPLC/SURVEYOR nuclease: a sensitive, rapid and affordable method to analyze BRCA1 and BRCA2 mutations in breast cancer families.Adipokines in hereditary breast cancer patients and healthy relatives.A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model.VEGF and TWIST1 in a 16-biomarker immunoprofile useful for prognosis of breast cancer patients.Innovative technology for cancer risk analysis.MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitors.Comment on 'Renewed interest in the progesterone receptor in breast cancer'.HOX gene methylation status analysis in patients with hereditary breast cancerBRCA Unclassified Variants: How Can They be Classified?Unclassified variants in BRCA genes: guidelines for interpretationMaternal and paternal lineage double heterozygosity alteration in familial breast cancer: a first case reportImmunological mutational signature in adenosquamous cancer of pancreas: an exploratory study of potentially therapeutic targetsGene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot StudyMolecular Characterization of a Long-Term Survivor Double Metastatic Non-Small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma Treated with Gefitinib in Combination with Gemcitabine Plus Nab-Paclitaxel and mFOLFOX6 as First and Second Line The
P50
Q28073891-ACBF71E4-A33B-4BD6-8CC8-73EBED2CAC47Q30384301-A8CFF4AD-FB64-4DF5-8346-A4E8BFAF95A2Q33728131-18C98B0B-E2E8-479C-8858-7BB54C65570FQ34551543-0590862B-32A3-40BC-8136-D410BF4D0E4CQ34599527-F65E56CF-2731-41E9-A916-0109C271B378Q34687031-BA9DBFB0-F95A-4DCA-A9DD-429AEDF406D5Q35238499-5047D61A-FBCF-45EB-B76A-8BB8130101C6Q36029740-3D6B3815-35CB-4297-BE5D-A203686AC2BBQ36322476-924D2853-54E8-451A-B38E-5AD018711FEAQ36329312-5CAC451C-DAB5-4938-BA50-24858C0FF7B9Q36413928-18E2FFB0-5493-459E-A1C5-5A30154BEAA1Q37013255-34122B93-8215-45A5-B197-DD21499ED11BQ37620662-8135E01A-B84C-4C71-9922-AD01D6FB6A6FQ37697004-F2FCA370-0CD1-440C-A2EA-F43884F1EEB4Q38153181-32725B96-ED85-4B53-AB79-60F9CBB307BBQ38167890-3DB311C7-F9B4-4483-9613-82B6EAD264A6Q38216171-5FBE95EB-37DD-49BD-B008-6856D17E6889Q40323342-3512F6ED-742A-4D5E-B818-2069328AB100Q41091405-D84C3A4D-C913-4354-8851-11174AE7F33AQ41387543-9E0DCAE6-BEA1-49DF-A7F3-1594FF4AF863Q44770193-26CD6474-0812-4BB5-81F0-28CBB27899EEQ45068453-9B8B2E28-027E-416E-AFCB-30A8C9C337CFQ47129182-C7968DC5-E413-4664-8B97-88A9B659232DQ47654723-404838DF-075E-4B9B-9537-2472C2D56DDAQ48177300-277FBE6C-AFB9-4886-A7FD-4113B4017602Q51058266-5183844C-7953-45F4-8CDC-58A1E983E931Q53435007-EBB3BA86-F719-482E-A4A7-E55181C1B33EQ55554746-34F9A4FB-842F-41F7-88A5-72B7E1BAB4E6Q60170538-ED50419A-79C3-49CD-85EF-640CDB8102BCQ60170541-7ADC8AA1-7F68-46FB-ABB7-352F4B47307FQ60170551-4FC4BC1A-5B6F-4F70-8A85-718AC9E7686CQ60170552-C4A424FE-C3F8-4D0F-AF93-9DFAC255051DQ88117846-9A822360-21C5-49B3-A2AF-01949F57BC71Q91658635-B6AEE6AF-3B12-41A7-A3B5-58825F1A2534Q92409916-5D18318F-EE74-4ABE-9B44-D011C634EC5F
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Simona De Summa
@ast
Simona De Summa
@en
Simona De Summa
@es
Simona De Summa
@nl
type
label
Simona De Summa
@ast
Simona De Summa
@en
Simona De Summa
@es
Simona De Summa
@nl
prefLabel
Simona De Summa
@ast
Simona De Summa
@en
Simona De Summa
@es
Simona De Summa
@nl
P106
P1153
36522061900
P21
P31
P496
0000-0001-9607-3754